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Available online at www.sciencedirect.comVaccines aim to establish or strengthen immune responses but
are also effective for the treatment of allergy. The latter is
surprising because allergy represents a hyper-immune
response based on immunoglobulin E production against
harmless environmental antigens, i.e., allergens. Nevertheless,
vaccination with allergens, termed allergen-specific
immunotherapy is the only disease-modifying therapy of allergy
with long-lasting effects. New forms of allergy diagnosis and
allergy vaccines based on recombinant allergen-derivatives,
peptides and allergen genes have emerged through molecular
allergen characterization. The molecular allergy vaccines allow
sophisticated targeting of the immune system and may
eliminate side effects which so far have limited the use of
traditional allergen extract-based vaccines. Successful clinical
trials performed with the new vaccines indicate that broad
allergy vaccination is on the horizon and may help to control the
allergy pandemic.
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Introduction
Allergy is an immunoglobulin E (IgE)-mediated hyper-
sensitivity disease affecting more than 25% of the popu-
lation [1]. Allergic patients suffer from a broad variety of
symptoms (e.g., rhinoconjunctivitis, asthma, dermatitis,
gastrointestinal symptoms, life-threatening systemic ana-
phylaxis) upon allergen contact. Allergen-specific immu-
notherapy (SIT), the therapeutic vaccination with the
disease-causing allergens is a clinically effective treatment
for allergy which unlike symptomatic pharmacotherapy,
modifies the underlying pathological immune response
and seems to have long-lasting effects [2]. In 1911 L.
Noon published the first successful immunotherapy trial
which he had performed in grass pollen-allergic patients
Open access under CC BY-NC-ND license.Current Opinion in Immunology 2012, 24:354–360 using pollen extracts administered by subcutaneous
immunization [3]. In his classical publication
(Figure 1) he referred to the work by W.P. Dunbar,
who not only had identified pollen grains as allergen
source but also had succeeded in producing antisera by
immunizing animals with pollen extracts [4]. Moreover,
Dunbar showed that these antisera prevented allergic
symptoms when patients were exposed to allergens in
provocation tests. The fact that vaccination with aller-
gens can be used to treat a hypersensitivity disease is
surprising. The dominant explanation for this effect is
that SIT induces counter IgG responses towards the
disease-causing allergens which interfere with aller-
gen-specific IgE responses. The latter has been demon-
strated in a classical study already in 1935 [5]. Since then,
many studies support the concept that the induction of
allergen-specific blocking IgG antibodies is a major
mechanism of SIT but also cellular mechanisms are
discussed and investigated [2].
Although SIT is a clinically effective treatment, it has
been recognized that the use of natural allergen extracts
for the preparation of the vaccines is a major bottleneck
for its further development towards a broadly used treat-
ment. In this context, several studies have demonstrated
the poor quality of allergen extracts which may lack
important allergens and show unpredictable compositions
[6–8,9]. Another major problem of SIT is that the
administration of allergens can cause severe side effects
[9]. Therefore, SIT is limited to specially trained phys-
icians, it requires the multiple application of increasing
allergen doses to reach the therapeutically effective main-
tenance doses and thus only relatively few allergic
patients can benefit from SIT.
However, during the last 25 years, molecular cloning
techniques have enabled the isolation of allergen-
encoding cDNAs from various allergen sources and
the subsequent production of allergens in recombinant
form [10]. Recombinant allergens have facilitated the
investigation of the pathomechanisms of allergy using
clinically relevant allergens in patients. In vitro and in
vivo diagnostic tests based on recombinant allergens,
epitopes and peptides have been developed which allow
for a more precise diagnosis of allergy and monitoring of
immune responses during treatment (Figure 2)
(reviewed in [10]). Most importantly, the availability
of allergen sequences and structures has allowed the
development of new sophisticated allergy vaccines
which have entered successful clinical evaluation
and hold promise that more effective, safe and con-
venient allergy vaccines become soon available andwww.sciencedirect.com
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Figure 1
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Classical publication of the first immunotherapy trial conducted by L.
Noon from 1911, highlighting the earlier experiments performed by WP
Dunbar supporting that SIT is a vaccine approach. Reprinted from [3]
with permission.it even seems that prophylactic vaccination is on the
horizon [10].
Allergen-based diagnosis and monitoring of
immune responses: Towards better
prescription and understanding of SIT
mechanisms.
Allergen-SIT is a form of therapeutic vaccination and
hence requires that the disease-causing allergens are ident-
ified for prescription of the correct vaccine. Diagnostic tests
based on recombinant allergen molecules allow the precise
determination of IgE reactivities to the individual allergen
molecules leading to better understanding of cross-reactiv-
ities [11]. Furthermore, component testing identifies
the allergen sources primarily responsible for allergicwww.sciencedirect.com sensitization in different populations and thus forms a basis
for better prescription of SIT. A recent study demonstrated
that the detailed knowledge of the molecular IgE reactivity
profiles profoundly changed the prescription of allergy
vaccines among allergologists [12]. Using diagnostic tests
based on recombinant bee and wasp allergens devoid of
cross-reactive carbohydrate epitopes [13] it was shown that
it is possible to discriminate genuinely bee and wasp-
sensitized patients from double-sensitized patients, allow-
ing more precise prescription of venom SIT. In fact,
clinically non-relevant cross-reactive carbohydrate epi-
topes were also shown to impair the diagnosis of cat allergy
[14] which can be achieved with non-glycosylated recom-
binant cat allergens [15].
Several studies conducted in food allergic patients
indicate that component-resolved allergy diagnosis allows
predicting whether individuals are prone to develop mild
or more severe manifestations of food allergy [16–18].
Such tests are useful for preventive measures such as diet
and may pave the road towards vaccination against food
allergy. In this context, clinical studies have shown that
oral immunotherapy, may be effective for the treatment
of milk, egg and peanut allergy [19–21]. Several studies
highlight the usefulness of diagnostic allergy tests based
on micro-arrayed allergens which allow the simultaneous
detection of IgE reactivities against a large number of
allergens with small blood samples [16,22,23].
Recombinant allergen components, epitopes and pep-
tides have been used to study the effects of SIT in
patients (reviewed in [2,9,10]). Studies using recombi-
nant allergens for monitoring of SIT re-emphasized the
importance of blocking IgG antibodies for the prevention
of allergen-induced effector cell degranulation [24,25].
On the basis of the availability of allergen sequences it has
become possible to produce MHCII tetramers for
monitoring allergen-specific T cell responses in the
course of disease and during SIT [26,27].
Mechanisms of SIT
Besides classical injection immunotherapy (SCIT) also
other application routes for SIT have been investigated.
Many clinical studies based on sublingual administration
of allergens (SLIT) have been conducted and it seems
that this treatment is clinically effective, albeit less than
injection immunotherapy. Also the immunological mech-
anisms underlying SLIT are less well understood than
those of SCIT. A recent study proposed that IgE-
mediated allergen uptake by mucosal APCs may lead
to an increased production of immunoregulatory cyto-
kines like IL-10 and TGF-b [28]. Yet SLIT induces only
low levels of allergen-specific IgG but rather boosts
allergen-specific IgE [29]. By contrast, it has been demon-
strated in immunotherapy trials using purified recombi-
nant wildtype allergens for subcutaneous vaccination that
the induction of allergen-specific IgG antibodies wasCurrent Opinion in Immunology 2012, 24:354–360
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Demonstration of the impact of the knowledge of allergen genes and allergen sequences/structures for the development of new forms of allergy
diagnosis, therapy monitoring and treatment.associated with the reduction of symptoms, medication
intake and sensitivity to the allergen [30]. Vaccination-
induced allergen-specific IgG thus occupies the binding
sites for IgE on the allergens and blocks allergen-induced
effector cell activation [25] as well as IgE-facilitated anti-
gen presentation of allergens to T cells [31]. The latter
mechanism may explain the reduced allergen-specific T
cell activation in SIT-treated patients as an antibody-
mediated effect. Interestingly, it was suggested that
besides epitope-specificity, affinity may play an important
role for the effects of blocking antibodies [32]. Already in
earlier SCIT trials with recombinant hypoallergenic aller-
gen derivatives and CpG-modified allergens it has been
shown that the induction of allergen-specific IgG is associ-
ated with a reduction of the boosts of allergen-specific IgE
production occurring after seasonal allergen exposure and
represents another important mechanism for the effects of
SCIT [33,34]. The mechanisms underlying SCIT with
hypoallergenic allergen-derivatives have been summar-
ized in a recent review [35].
In addition to established subcutaneous injection of aller-
gens and allergen-derivatives intralymphatic administration
of allergy vaccines has been suggested for reducing side
effects and obtaining increased allergen-specific IgG butCurrent Opinion in Immunology 2012, 24:354–360 the latter has not yet been convincingly demonstrated [36].
Furthermore, epicutaneous allergen administration has
been proposed  as an alternative route to subcutaneous
injection. Studies performed in experimental animal
models indicate that epicutaneous allergen application
may have effects on systemic allergen-specific immune
responses [37,38] but effects on systemic immunity have
not been studied in allergic patients [39].
Studies performed with T cell epitope-containing pep-
tides which do not induce allergen-specific IgG responses
indicate that SIT may also selectively address allergen-
specific T cell responses. The administration of peptides
from the major cat allergen Fel d 1 induced a reduction of
delayed type, presumably T cell-mediated symptoms
[40]. The induction of IL-10 producing T regulatory cells
and the existence of linked immunological suppression
have been suggested as possible underlying mechanisms
[41]. Indeed, it has been demonstrated in a TCR-trans-
genic model that Th1 cells as well as Fox p 3+ regulatory
T cells are able to suppress the effector functions of Th2
cells [42,43]. However, the effects of T cell peptide
therapy on allergen-induced mast cell degranulation
and acute allergic inflammation observed in clinical trials
are modest and deserve further investigation [44].www.sciencedirect.com
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sophisticated targeting of the immune system
When the sequences of the first major allergens became
available and their T cell epitopes could be mapped using
peptide technology, the concept of inducing T cell tol-
erance with non-IgE reactive but T cell epitope-contain-
ing peptides emerged as the first targeted molecular SIT
approach [45,46]. Currently several immunotherapy stu-
dies with allergen-derived T cell peptides are ongoing of
which a recent study performed for cat allergy showed
beneficial effects on late phase allergic symptoms [40].
Although there is evidence for linked immunological
suppression [41], it is very likely that the T cell peptide
approach will require that several different allergen-
derived peptides are included in the vaccine in order
to cover the diverse spectrum of T cell epitopes recog-
nized by allergic patients.
Several research groups have therefore developed recom-
binant hypoallergenic allergen derivatives which are
characterized by reduced IgE reactivity but preserved
T cell epitopes to reduce IgE-mediated side effects
during SIT (reviewed in [35,47]). These molecules are
made by reducing IgE reactivity and maintaining the
spectrum of the T cell epitopes of the original wildtype
allergens by various recombinant DNA technologies such
as mutation, reassembly, or fragmentation. The first
immunotherapy trial with recombinant allergens was
actually performed with recombinant hypoallergenic
derivatives of the major birch pollen allergen Bet v 1
eleven years ago. Meanwhile, successful phase III SIT
trials with recombinant Bet v 1 hypoallergens have been
performed [48]. The analyses of SCIT trials which have
been performed with recombinant hypoallergenic aller-
gen derivatives revealed the induction of allergen-specific
blocking IgG antibodies as a major underlying mechan-
ism. Several recombinant hypoallergens for the treatment
of allergy to house dust mites, birch pollen and cat have
been constructed and characterized in in vitro and exper-
imental animal models recently [49–53,54]. Different
strategies for their construction have been used such as
reassembly of sequence elements [49,50,55], oligomeri-
zation to increase IgG responses [51], epitope grafting
inducing altered fold [54], coupling to Vitamin D3 for
immunomodulation [52], random PCR-based sequence
evolution [56] and mutations [53].
Successful clinical SCIT trials have been performed with
recombinant allergens made exactly as their natural
counterparts for birch and grass pollen allergy [30,57].
These studies also demonstrated that clinical efficacy and
reduction of sensitivity are associated with the develop-
ment of allergen-specific IgG antibodies [48].
In the course of clinical studies performed with non-
IgE-reactive T cell peptides and recombinant hypoal-
lergenic allergen derivatives it has been recognized thatwww.sciencedirect.com allergen-derived T cell epitopes can induce late phase,
non-IgE-mediated side effects. In an attempt to eliminate
IgE as well as T cell-mediated side effects a new type of
allergy vaccines has therefore been developed [10]. This
approach is based on the identification of allergen peptides
which are part of the major IgE binding sites on allergens
but per se lack IgE and allergenic activity [58]. These
peptides which are typically between 20 and 35 amino
acids in length can either be coupled chemically to a carrier
protein [59–61] or produced as recombinant fusion proteins
with a carrier protein [62,63]. Immunization with carrier-
bound allergen peptides induces and focuses IgG anti-
bodies towards the IgE epitopes on allergens with the T
cell help of the carrier protein and thus do not activate
allergen-specific T cells. Since the presence of allergen-
specific T cell epitopes is reduced in these vaccines they
should bypass T cell-mediated side effects [9]. Viral
carrier proteins have been suggested in order to achieve
immunomodulation and to induce a beneficial antiviral
immunity in addition to protection against allergens [64]. A
similar approach aiming at the induction of allergen-
specific IgG antibodies is based on the use of allergen
mimotopes [65].
Since allergen-specific IgG antibodies seem to play a
major role in antagonizing allergic immune responses,
passive immunization with allergen-specific IgG anti-
bodies has emerged as another possibility for allergy
vaccination [66]. In fact, human allergen-specific IgG
antibodies capable of blocking even polyclonal IgE recog-
nition of allergens have been developed [67,68]. More-
over, it has been demonstrated in experimental animal
models that maternal immunization generates allergen-
specific IgG which is transmitted to the offspring and can
prevent allergic sensitization [69,70,71].
On the basis of the finding that transfer of hematopoetic
stem cells expressing major allergens can induce robust
allergen-specific tolerance in a preventive model of
allergy [72,73], membrane-anchored and secreted aller-
gen-expressing stem cells have been recently engineered
to delineate the mechanisms of tolerance [74]. Gene
therapy is an interesting preventive approach for allergy
but will require the simultaneous assembly of major
allergen epitopes recognized in certain populations and
it will be necessary to develop safe treatment protocols
[74] (Figure 2).
Another interesting approach for immunomodulation is
vaccination with allergen-encoding RNA which in exper-
imental animal models has been shown to prevent allergic
sensitization for several allergens [75].
Outlook: broad therapeutic vaccination and
prophylactic vaccines?
Table 1 provides an overview of different strategies for
SIT based on their putative immunological mechanisms.Current Opinion in Immunology 2012, 24:354–360
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Table 1
Strategies for SIT
Human Animal
Active induction of a counter
immune response
24, 25, 30, 33,
34, 36, 57
49–55, 59–65
Peripheral tolerance 19–21, 40,
44, 45,
37, 38, 41
Central tolerance 72, 73
Immune modulation 75
Passive immunization 69–71Certain strategies such as SCIT with recombinant aller-
gen, hypoallergens, T cell peptides and carrier-bound
allergen peptides are already in clinical evaluation and
hold promise that allergen molecule-based vaccines will
be soon available for broad, safe and convenient thera-
peutic vaccination. However, more controlled immu-
notherapy studies with defined allergen, allergen
derivatives and epitopes are needed to further delineate
the mechanisms of SIT and optimize the vaccines. Stu-
dies performed in experimental animal models and non-
allergic individuals with engineered allergen derivatives
and epitopes will be necessary to develop prophylactic
vaccination and tolerance induction strategies for the
prevention of allergies which may ultimately halt the
allergy pandemic.
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